FDA-2012-N-0967 – Julie Flygare

Representing People with Narcolepsy at the FDA

By julie | October 26, 2012 |

Yesterday, I had the extraordinary honor of visiting the Food and Drug Administration (FDA) to urge them to include Narcolepsy in the ground-breaking Patient-Focused Drug Development initiative. I was #19 to sign up on the disease nomination speaker list, even though I arrived 15 minutes before registration technically opened. The large conference room quickly filled…

Join me: Urge FDA to include Narcolepsy in new patient-focused initiative

By julie | October 23, 2012 |

The Food and Drug Administration (FDA) has nominated “narcolepsy” for a groundbreaking new patient-focused drug development initiative. Only 20 diseases will be chosen. Please join me in urging the FDA to select “narcolepsy” for this important effort. About the FDA Initiative:“Narcolepsy” is one of 39 disease areas nominated for a new FDA initiative to better inform the FDA’s drug and…